Literature DB >> 12857999

New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.

Mark L Tykocinski1, Aoshuang Chen, Jui-Han Huang, Matthew C Weber, Guoxing Zheng.   

Abstract

Antigen-presenting cells (APC) can be refaced with "protein paints" that change the appearance of their T cell-oriented trans signal arrays. Our group has developed three categories of protein paints suitable for this kind of APC engineering: artificial glycosylphosphatidylinositol (GPI) proteins, palmitated-protein A:Fc*1 fusion protein conjugates, and trans signal converter proteins. Protein paints have been devised with either immune enhancement or suppression in mind. Costimulator * GPI and palmitated-protein A costimulator * Fcgamma1 conjugates can be used to augment the immune-activating potential of tumor cells. Alternatively, protein paints can be designed to transform APC into artificial veto cells, in essence creating Trojan horses capable of inhibiting pathogenic T cells. Trans signal converter proteins (TSCP) have been devised for this purpose. Our first paradigmatic inhibitory TSCP, CTLA-4 * Fas ligand, binds to APC, and in so doing, simultaneously blocks B7 costimulation (via CTLA-4) and sends inhibitory trans signals (via Fas ligand) to T cells with dramatic efficacy. Protein transfer offers a number of advantages over gene transfer in facilitating quantitative and combinatorial protein expression and simplifying in vivo applications; the palette of protein paints with immunotherapeutic potential will undoubtedly continue to evolve.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857999     DOI: 10.1385/IR:27:2-3:565

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  75 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

Review 2.  Costimulatory regulation of T cell function.

Authors:  C A Chambers; J P Allison
Journal:  Curr Opin Cell Biol       Date:  1999-04       Impact factor: 8.382

3.  Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events.

Authors:  J Fayen; J H Huang; S Ferrone; M L Tykocinski
Journal:  Int Immunol       Date:  1998-09       Impact factor: 4.823

4.  Reduction of the in vitro cytotoxic lymphocyte response produced by in vivo exposure to semiallogeneic cells: recruitment or active suppression?

Authors:  R G Miller; R A Phillips
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

5.  The use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions.

Authors:  S A Kim; J S Peacock
Journal:  J Immunol Methods       Date:  1993-01-14       Impact factor: 2.303

Review 6.  Antigen-presenting cell engineering. The molecular toolbox.

Authors:  M L Tykocinski; D R Kaplan; M E Medof
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

Review 7.  Antigen-presenting cell types.

Authors:  S C Knight; A J Stagg
Journal:  Curr Opin Immunol       Date:  1993-06       Impact factor: 7.486

8.  Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents.

Authors:  K A Candido; K Shimizu; J C McLaughlin; R Kunkel; J A Fuller; B G Redman; E K Thomas; B J Nickoloff; J J Mulé
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

9.  Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function.

Authors:  E B Brunschwig; E Levine; U Trefzer; M L Tykocinski
Journal:  J Immunol       Date:  1995-12-15       Impact factor: 5.422

10.  Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4+ T cells.

Authors:  Y Itoh; R N Germain
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

View more
  3 in total

1.  Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Authors:  Marjaneh Razmara; Brendan Hilliard; Azadeh K Ziarani; Ramachandran Murali; Srikanth Yellayi; Mustafa Ghazanfar; Youhai H Chen; Mark L Tykocinski
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 2.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

3.  Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of low systemic toxicity.

Authors:  Sharon H Chou; Aditya V Shetty; Yajun Geng; Lipeng Xu; Gnanasekar Munirathinam; Anne Pipathsouk; Isaiah Tan; Timothy Morris; Bin Wang; Aoshuang Chen; Guoxing Zheng
Journal:  Cancer Immunol Immunother       Date:  2012-11-04       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.